Unable to Compel Recall, FDA Asks Doctors Not to Use NuVision’s Products
This article was originally published in The Gold Sheet
Executive Summary
Dallas compounding pharmacy brushes off FDA’s concerns about sterility assurance despite complaints about one injectable drug product and results of the agency’s inspection. While NuVision asserts compliance with USP requirements, FDA warns physicians that the injectables NuVision compounds may not be sterile.
You may also be interested in...
US FDA Would Get Mandatory Recall Authority For Drugs Under House Funding Bill
The change would let FDA forcibly pull prescription and over-the-counter drugs off the market just like vaccines, medical devices and other products.
FDA Warns Consumers Not To Use Sterile Drugs Made By Pacifico National After Firm Refuses Recall Requests
After Melbourne, Florida, outsourcer resisted entreaties to recall sterile drugs over contamination and eye infections, the FDA warned consumers not to use sterile drugs compounded by the firm, Pacifico National, doing business as AmEx Pharmacy.
A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: